| [1] |
Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus[J]. World J Gastroenterol, 2006, 12(47):7561-7567.
|
| [2] |
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022.
|
| [3] |
Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(2):439-474.
|
| [4] |
Shi J, Lai EC, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2010, 17(8):2073-2080.
|
| [5] |
Li SH, Wei W, Guo RP, et al. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors[J]. Med Oncol, 2013, 30(4):696.
|
| [6] |
全国肝癌合并癌栓诊治研究协作组．肝细胞癌合并门静脉癌栓多学科诊治中国专家共识（2016年版）[J]．中华医学杂志，2016，15(18):411-416.
|
| [7] |
Wang K, Guo WX, Chen MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity matching score analysis[J]. Medicine, 2016, 95(11):e3015.
|
| [8] |
中华人民共和国卫生部．原发性肝癌诊疗规范（2011版）[J]. 中华肝脏病杂志，2012，20(6):929-946.
|
| [9] |
Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study[J]. Surgery, 2005, 137(4):403-410.
|
| [10] |
Peng B, Liang L, He Q, et al. Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus[J]. Hepatogastroenterology, 2006, 53(69):415-419.
|
| [11] |
Chen XP, Qiu FZ, Wu ZD, et al. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma[J]. Ann Surg Oncol, 2006, 13(7):940-946.
|
| [12] |
Peng ZW, Guo RP, Zhang YJ, et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Cancer, 2012, 118(19):4725-4736.
|
| [13] |
Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma[J]. Gastroenterology, 2014, 146(7):1691-1700.
|
| [14] |
Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319):1734-1739.
|
| [15] |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
|
| [16] |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
|
| [17] |
Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study[J]. Ann Surg Oncol, 2011, 18(2):413-420.
|
| [18] |
Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258(2):627-634.
|
| [19] |
Xue TC, Xie XY, Zhang L, et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis[J]. BMC Gastroenterol, 2013(13):60.
|
| [20] |
Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses[J]. Radiology, 2013, 269(2):603-611.
|
| [21] |
Zhu K, Chen J, Lai L, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study[J]. Radiology, 2014, 272(1):284-293.
|
| [22] |
Yang M, Yuan JQ, Bai M, et al. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis[J]. Mol Biol Rep, 2014, 41(10):6575-6582.
|
| [23] |
Zhang L, Hu P, Chen X, et al. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis[J]. PLoS One, 2014, 9(6):e100305.
|
| [24] |
Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities[J]. Int J Radiat Oncol Biol Phys, 2013, 87(1):22-32.
|
| [25] |
Zhang XB, Wang JH, Yan ZP, et al. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization[J]. Cancer, 2009, 115(6):1245-1252.
|
| [26] |
Zeng ZC, Fan J, Tang ZY, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J]. Int J Radiat Oncol Biol Phys, 2005, 61(2):432-443.
|
| [27] |
Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2012, 82(5):2004-2011.
|
| [28] |
Song DS, Song MJ, Bae SH, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol, 2015, 50(4):445-454.
|
| [29] |
Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression[J]. Br J Cancer, 2005, 93(5):557-564.
|
| [30] |
广东省抗癌协会肝癌专业委员会. 肝细胞肝癌合并门静脉癌栓多学科团队综合治疗广东专家共识(2015年版)[J]. 中华消化外科杂志，2015，14(9):694-701.
|